Navigating FDA Regulations for the Development of Artificial Intelligence Technologies in Plastic Surgery

Area of Science:

• Medical Technology
• Artificial Intelligence in Surgery
• Regulatory Science

Background:

• Artificial intelligence (AI) technologies are increasingly integrated into plastic surgery, offering advancements in diagnostics, treatment planning, and outcome prediction.
• Clinical adoption of AI in plastic surgery necessitates understanding and adherence to U.S. Food and Drug Administration (FDA) regulatory frameworks.
• The FDA's Digital Health Center of Excellence provides resources for AI-based medical device development.

Purpose of the Study:

• To review current FDA regulatory pathways for AI applications in plastic surgery.
• To examine challenges in regulating adaptive AI technologies within plastic surgery.
• To provide practical recommendations for developers of AI tools in plastic surgery.

Main Methods:

• Review of FDA regulatory pathways: 510(k), De Novo, and Premarket Approval.
• Examination of the FDA's total product lifecycle approach and real-world performance monitoring.
• Discussion of Good Machine Learning Practices (GMLP) and collaborative frameworks.

Main Results:

• Outlines key FDA regulatory processes applicable to AI in plastic surgery.
• Highlights challenges specific to adaptive AI and the need for lifecycle monitoring.
• Emphasizes the importance of GMLP and inter-agency collaboration.

Conclusions:

• Effective navigation of FDA regulations is essential for the successful development and implementation of AI in plastic surgery.
• Plastic surgeons and researchers must prioritize algorithm transparency, explainability, and bias mitigation.
• Adherence to regulatory standards ensures the delivery of safe, effective AI-driven patient care.